ES2531464T3 - Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada - Google Patents

Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada Download PDF

Info

Publication number
ES2531464T3
ES2531464T3 ES09768986.3T ES09768986T ES2531464T3 ES 2531464 T3 ES2531464 T3 ES 2531464T3 ES 09768986 T ES09768986 T ES 09768986T ES 2531464 T3 ES2531464 T3 ES 2531464T3
Authority
ES
Spain
Prior art keywords
vwf
fviii
modified
life
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09768986.3T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Weimer
Stefan Schulte
Hubert Metzner
Ulrich Kronthaler
Holger Lind
Wiegand Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Application granted granted Critical
Publication of ES2531464T3 publication Critical patent/ES2531464T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES09768986.3T 2008-06-24 2009-06-24 Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada Active ES2531464T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08011429 2008-06-24
EP08011429 2008-06-24
PCT/EP2009/004549 WO2009156137A1 (en) 2008-06-24 2009-06-24 Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life

Publications (1)

Publication Number Publication Date
ES2531464T3 true ES2531464T3 (es) 2015-03-16

Family

ID=40042814

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09768986.3T Active ES2531464T3 (es) 2008-06-24 2009-06-24 Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
ES14192277.3T Active ES2654336T3 (es) 2008-06-24 2009-06-24 Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14192277.3T Active ES2654336T3 (es) 2008-06-24 2009-06-24 Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada

Country Status (12)

Country Link
US (2) US8575104B2 (enExample)
EP (2) EP2865760B1 (enExample)
JP (1) JP5832285B2 (enExample)
KR (2) KR101507718B1 (enExample)
CN (2) CN103739712B (enExample)
AU (1) AU2009262476C1 (enExample)
CA (1) CA2728012C (enExample)
DK (2) DK2291523T3 (enExample)
ES (2) ES2531464T3 (enExample)
PL (1) PL2291523T3 (enExample)
RU (1) RU2528855C2 (enExample)
WO (1) WO2009156137A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
RU2528855C2 (ru) 2008-06-24 2014-09-20 Цсл Беринг Гмбх Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
WO2011060242A2 (en) 2009-11-13 2011-05-19 Talecris Biotherapeutics, Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
US20130040888A1 (en) 2010-02-16 2013-02-14 Novo Nordisk A/S Factor VIII Molecules With Reduced VWF Binding
US9493543B2 (en) 2010-02-16 2016-11-15 Novo Nordisk A/S Factor VIII fusion protein
CN102812039B (zh) * 2010-02-16 2016-01-20 诺沃—诺迪斯克有限公司 缀合蛋白质
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
EP3412305B1 (en) 2011-06-10 2021-01-06 Baxalta GmbH Treatment of coagulation disease by administration of recombinant vwf
RS59670B1 (sr) * 2012-01-12 2020-01-31 Bioverativ Therapeutics Inc Himerni polipeptidi faktora viii i njihove upotrebe
EP2814955A1 (en) * 2012-02-14 2014-12-24 Portola Pharmaceuticals, Inc. Process for making recombinant antidote to factor xa inhibitor
DK3564260T5 (da) 2012-02-15 2024-09-02 Bioverativ Therapeutics Inc Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
EA201491388A1 (ru) * 2012-02-15 2015-01-30 Байоджен Айдек Ма Инк. Рекомбинантные белки фактора viii
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
CN104661674A (zh) * 2012-07-11 2015-05-27 阿穆尼克斯运营公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
WO2014210558A1 (en) * 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker with xten and its uses thereof
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
WO2015066769A1 (en) 2013-11-08 2015-05-14 Csl Ltd. New method to concentrate von willebrand factor or complexes thereof
CN114736305B (zh) * 2014-01-10 2023-05-05 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
WO2015188224A1 (en) 2014-06-13 2015-12-17 Csl Limited Improved production of recombinant von willebrand factor in a bioreactor
DE102014011653A1 (de) * 2014-06-20 2015-12-24 Ulrich Loos Nachweis von Autoantikörpern gegen den TSH-Rezeptor
US10253088B2 (en) 2014-07-02 2019-04-09 CSL Behring Lengnau AG Modified von Willebrand Factor
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
MX388739B (es) * 2015-02-06 2025-03-20 Univ North Carolina Chapel Hill Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
KR20180012303A (ko) 2015-05-22 2018-02-05 체에스엘 베링 리컴비넌트 퍼실리티 아게 변형된 폰 빌레브란트 인자의 제조 방법
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
WO2017112895A1 (en) * 2015-12-23 2017-06-29 Haplomics, Inc. F8 gene repair
CA3010720A1 (en) * 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
DK3400238T3 (da) * 2016-01-07 2021-07-26 CSL Behring Lengnau AG Muteret von willebrand faktor
US12171808B2 (en) * 2016-05-20 2024-12-24 Octapharma Ag Glycosylated VWF fusion proteins with improved pharmacokinetics
KR102175878B1 (ko) * 2016-06-24 2020-11-06 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
SG10201912360SA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
US11890327B2 (en) 2016-11-11 2024-02-06 CSL Behring Lengnau AG Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
IL308416B2 (en) 2016-12-02 2025-08-01 Bioverativ Therapeutics Inc Methods of treating hemophilic arthropathy using chimeric clotting factors
CA3068098A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
BR112020000321A2 (pt) 2017-07-07 2020-07-14 Baxalta Incorporated método para tratamento de sangramento gastrointestinal em um sujeito com doença de von willebrand.
FI3648787T3 (fi) * 2017-07-07 2025-01-20 Takeda Pharmaceuticals Co Elektiiviseen leikkaustoimenpiteeseen osallistuvien vaikeaa von willebrandin tautia sairastavien potilaiden hoito antamalla rekombinanttia vwf:ää
CA3072003A1 (en) 2017-08-23 2019-02-28 Csl Behring Gmbh Method for virus filtration of von willebrand factor
MA52630B1 (fr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Procédés de traitement de l'hémophilie a
EP3897831A1 (en) * 2018-12-23 2021-10-27 CSL Behring LLC Donor t-cells with kill switch
US12128090B2 (en) 2019-02-01 2024-10-29 Takeda Pharmaceutical Company Limited Methods of prophylactic treatment using recombinant VWF (rVWF)
CN111592591B (zh) * 2020-06-17 2021-12-14 博雅生物制药集团股份有限公司 一种人血管性血友病因子/人凝血因子ⅷ复合物的制备方法及产物和应用
CN117720671B (zh) * 2024-01-30 2024-06-14 南通大学 具有自组装性能的重复结构单元重组蛋白ⅠAⅠB-ⅠAⅠBrQTY及应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
ATE502958T1 (de) 1996-04-24 2011-04-15 Univ Michigan Gegen inaktivierung resistenter faktor viii
US6103077A (en) * 1998-01-02 2000-08-15 De Nora S.P.A. Structures and methods of manufacture for gas diffusion electrodes and electrode components
EP1079805B1 (en) 1998-04-27 2004-11-24 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
EP1148063A1 (de) 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
EP1351986A2 (en) 2001-01-12 2003-10-15 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
WO2002103024A2 (en) 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
EP1497330B1 (en) 2002-04-29 2010-04-07 Stichting Sanquin Bloedvoorziening Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
WO2004052401A2 (en) * 2002-12-09 2004-06-24 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
EP2572732A1 (en) 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ATE497783T1 (de) * 2003-05-06 2011-02-15 Syntonix Pharmaceuticals Inc Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten
AU2004251145C1 (en) 2003-06-12 2011-04-14 Eli Lilly And Company GLP-1 analog fusion proteins
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
EP1670931A2 (en) 2003-09-05 2006-06-21 GTC Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR101483917B1 (ko) 2004-11-12 2015-01-16 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
PL1835938T3 (pl) * 2004-12-27 2014-01-31 Baxalta Inc Koniugaty polimer-czynnik von Willebrandta
WO2006108590A1 (en) 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation factor viii with enhanced stability and its derivates
CA2627478A1 (en) * 2005-10-28 2007-05-03 Dnavec Corporation Therapeutic method for blood coagulation disorder
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
MX2008012600A (es) 2006-03-31 2008-12-12 Baxter Int Factor viii pegilado.
PL2032607T5 (pl) 2006-06-14 2017-10-31 Csl Behring Gmbh Rozszczepialne proteolitycznie białko fuzyjne obejmujące czynnik krzepnięcia krwi
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
RU2528855C2 (ru) 2008-06-24 2014-09-20 Цсл Беринг Гмбх Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения
US9402754B2 (en) * 2010-05-18 2016-08-02 Abbott Cardiovascular Systems, Inc. Expandable endoprostheses, systems, and methods for treating a bifurcated lumen
RS59670B1 (sr) 2012-01-12 2020-01-31 Bioverativ Therapeutics Inc Himerni polipeptidi faktora viii i njihove upotrebe
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia

Also Published As

Publication number Publication date
KR101507718B1 (ko) 2015-04-10
JP2011525363A (ja) 2011-09-22
US20110183907A1 (en) 2011-07-28
KR20140090703A (ko) 2014-07-17
KR20110044978A (ko) 2011-05-03
ES2654336T3 (es) 2018-02-13
CN103739712A (zh) 2014-04-23
AU2009262476C1 (en) 2016-06-02
JP5832285B2 (ja) 2015-12-16
EP2865760B1 (en) 2017-10-11
EP2291523B1 (en) 2014-12-17
EP2865760A1 (en) 2015-04-29
HK1151068A1 (en) 2012-01-20
DK2291523T3 (en) 2015-03-23
CN102076855A (zh) 2011-05-25
PL2291523T3 (pl) 2015-05-29
AU2009262476B2 (en) 2014-06-26
US20140072561A1 (en) 2014-03-13
US9290561B2 (en) 2016-03-22
RU2011102366A (ru) 2012-07-27
RU2528855C2 (ru) 2014-09-20
KR101648734B1 (ko) 2016-08-18
AU2009262476A1 (en) 2009-12-30
DK2865760T3 (en) 2018-01-15
CA2728012C (en) 2017-10-31
WO2009156137A1 (en) 2009-12-30
CA2728012A1 (en) 2009-12-30
EP2291523A1 (en) 2011-03-09
US8575104B2 (en) 2013-11-05
CN103739712B (zh) 2016-10-05

Similar Documents

Publication Publication Date Title
ES2531464T3 (es) Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
EP2097096B1 (en) Modified coagulation factors with prolonged in vivo half-life
US8765915B2 (en) Modified coagulation factor VIIa with extended half-life
ES2657291T3 (es) Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
US9458223B2 (en) Von willebrand factor variants having improved factor VIII binding affinity
ES2844232T3 (es) Factor de Von Willebrand modificado
ES2349024T3 (es) Metodo para aumentar la recuperacion in vivo de polipeptidos terapeuticos.
DK2097096T3 (en) MODIFIED COAGULATION FACTORS WITH EXTENDED IN VIVO HALF TIME
ES2881701T3 (es) Factor de von Willebrand mutado
US20210163575A1 (en) Factor viii mutant expression vector with enhanced protein expression
AU2013202563A1 (en) Method of increasing the in vivo recovery of therapeutic polypeptides
HK1151068B (en) Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
AU2012258466A1 (en) Modified coagulation Factor VIIa with extended half-life